This triagonist approach combines GLP-1 and GIP receptor activity with glucagon-receptor signalling to modulate energy homeostasis and incretin pathways
Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 4069% of participants achieved 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43]
Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, and Egan JM
However, recent clinical evidence suggests prescription-based approachesincluding compounded GLP-1 medicationsmay address underlying metabolic factors that diet programs alone cannot target
Bjarnason NH, Henriksen EE, Alexandersen P, et al
Photo Credit: Adam Fisher, Baldwin Publishing 10 mins Cool and refreshing, this smoothie bowl is perfect for days when solid meals dont sound appealing